[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369042-105":59,"doc-detail-369042-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-efficacy-of-parp-inhibitors-in-metastatic-castration-resistant-prostate-cancer-with-homologous-recombination-repair-alteration-a-meta-analysis-based-on-subgroups-and-reconstructed-individual-patient-data","Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration - a meta-analysis based on subgroups and reconstructed individual patient data","","Meta-analysis evaluates poly(ADP-ribose) polymerase inhibitors (PARPIs) for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) alterations, focusing on subgroup effects and reconstructed individual patient data. Trials up to April 2025 were searched and hazard ratios or risk ratios pooled. Radiographic progression-free survival (rPFS) and overall survival (OS) served as main and key secondary endpoints, with heterogeneity, sensitivity, and publication bias assessed. Results from 1840 patients show improved rPFS and OS overall, with benefits concentrated in BRCA1/2.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-efficacy-of-parp-inhibitors-in-metastatic-castration-resistant-prostate-cancer-with-homologous-recombination-repair-alteration-a-meta-analysis-based-on-subgroups-and-reconstructed-individual-patient-data/369042/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-efficacy-of-parp-inhibitors-in-metastatic-castration-resistant-prostate-cancer-with-homologous-recombination-repair-alteration-a-meta-analysis-based-on-subgroups-and-reconstructed-individual-patient-data/369042.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this meta-analysis?","Question",{"text":112,"@type":113},"To determine the efficacy of PARP inhibitors in mCRPC patients, with emphasis on subgroup outcomes defined by specific HRR alterations using reconstructed individual patient data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which outcomes were analyzed as primary and secondary endpoints?",{"text":117,"@type":113},"Radiographic progression-free survival (rPFS) was the primary outcome. Secondary outcomes included overall survival (OS), PSA progression-free survival (PSA-PFS), and adverse events (AEs).",{"name":119,"@type":110,"acceptedAnswer":120},"How did PARP inhibitors perform in BRCA1/2 versus non-BRCA HRR alterations?",{"text":121,"@type":113},"PARP inhibitors showed prominent survival benefits in the BRCA1/2 subgroup, while no benefits were detected for rPFS and OS in the ATM subgroup and for OS in the CDK12 subgroup.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369042,1791185715,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data  \nFuxun Zhang, MDa,b , Zhirong Luo, MMa , Yang Xiong, MDc , Qi Xue, MMa , Xuyan Guo, MMa , Qiang Fu, MMa , Yong Jiao, MMa , Wei Zhang, MDa , Pati-Alam Alisha, MDb , Uzoamaka Adaobi Okoli, MDb,d ,*, Geng Zhang, MDa ,*  \nBackground: Treatment for metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) alteration remains a challenge. Recently published trials have evaluated the poly (ADP-ribose) polymerase inhibitors (PARPIs) in mCRPC. However, the efficacy in subgroup with specific HRR gene mutation and treatment protocol requires further elucidation. This meta-analysis aims to explore the efficacy of PARPIs based on subgroups and reconstructed individual patient data (IPD) .  \nMethods: Literature was searched using PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to April 2025. The primary outcome was radiographic progression-free survival (rPFS), and the secondary outcomes included overall survival (OS), prostatespecific antigen progression-free survival (PSA-PFS), and adverse events (AEs) . Hazard ratios (HRs) and risk ratios (RRs) were pooled as the indicators using inverse-variance and Mantel-Haenszel methods. IPD was reconstructed from Kaplan–Meier curve. Survival analysis was performed using Cox proportional hazards model based on the reconstructed IPD. Heterogeneity was assessed by I2 and sensitivity analysis. Publication bias was examined via contour-enhanced funnel plots.  \nResults: Data of 1840 mCRPC patients with HRR alteration from five pivotal phase III clinical trials were analyzed. PARPIs significantly improved overall rPFS (HR: 0.55) and OS (HR: 0.85) . PARPIs also prolonged rPFS across the subgroups defined by clinicopathologic features. InBRCA1/2 subgroup, survival benefits were prominent for rPFS (HR 0 .32) and OS (HR 0 .70) . For patients with non-BRCA alterations, no benefits of PARPIs were detected for rPFS and OS inATM subgroup, and for OS in CDK12 subgroup. Survival analyses indicated that PARPIs treatment was significantly associated with the improved rPFS (HR: 0.73, P \u003C 0.001) and PSA-PFS (HR: 0 .80, P = 0.020) in the overall population, and revealed OS benefit in BRCA1/2 subgroup (HR: 0.77, P = 0.030) . Comparing with monotherapy, combination regimen of PARPIs provided greater benefits for rPFS (HR: 0.56,  \nP \u003C 0.001)and OS (HR: 0.64. , P \u003C 0.001) .  \nConclusions: PARPIsimprove survival in mCRPC patients with BRCA1/2 mutation, but have no effect in those with ATM mutation. Comparing with PARPIs monotherapy, the combination regimen provides greater survival benefit in the overall population. Future investigation should validate these findings in real-world settings.  \nKeywords: individual patient data, poly (ADP-ribose) polymerase inhibitor, prostate cancer, survival, treatment  \naDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China, bDivision of Surgery & Interventional Science, University College London, London, UK, cDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China and dBasic and Translational Cancer Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria  \nFuxun Zhang, Zhirong Luo, and Yang Xiong contributed equally to this work. The Fourth Military Medical University is also named as AirForce Medical University. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n*Corresponding authors. Address: Division of Surgery & Interventional Science, University College London, London 710038, [UK. E-mail: u.okoli@ucl.ac.uk](UK. E-mail: u.okoli@ucl.ac.uk) (U.A. Okoli); Department of Urology, Tangdu","cbCair39RdtGTJT9","https://ap.wps.com/l/cbCair39RdtGTJT9","pdf",3904902,13,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What was the main goal of this meta-analysis?\",\"answer\":\"To determine the efficacy of PARP inhibitors in mCRPC patients, with emphasis on subgroup outcomes defined by specific HRR alterations using reconstructed individual patient data.\"},{\"question\":\"Which outcomes were analyzed as primary and secondary endpoints?\",\"answer\":\"Radiographic progression-free survival (rPFS) was the primary outcome. Secondary outcomes included overall survival (OS), PSA progression-free survival (PSA-PFS), and adverse events (AEs).\"},{\"question\":\"How did PARP inhibitors perform in BRCA1/2 versus non-BRCA HRR alterations?\",\"answer\":\"PARP inhibitors showed prominent survival benefits in the BRCA1/2 subgroup, while no benefits were detected for rPFS and OS in the ATM subgroup and for OS in the CDK12 subgroup.\"}]","Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration - a meta-analysis based on subgroups and reconstructed individual patient data | PDF",1790180314,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28103e4146284b3c036096ff8aa92ee4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a3ec2c9caa8b8293fe99ef3a184257a.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4b2f8030bb15c9f0808dbd724276b89.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ab13aba50770fb93b58a745b33fc118.webp",980,1306]